Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

GC Biopharma Presents Data Showing Higher Thrombotic Risk with Roche’s Hemlibra

Fineline Cube Aug 18, 2023

South Korea’s GC Biopharma (KRX: 006280) has presented evidence suggesting that Roche’s (SWX: ROG) hemophilia...

Company Drug

Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants

Fineline Cube Aug 18, 2023

Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...

Company

Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion

Fineline Cube Aug 18, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of...

Company Medical Device

NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing

Fineline Cube Aug 18, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...

Company Drug

Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug

Fineline Cube Aug 18, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...

Company Deals

CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology

Fineline Cube Aug 18, 2023

Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study

Fineline Cube Aug 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company

Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant

Fineline Cube Aug 17, 2023

China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing...

Company Deals

Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment

Fineline Cube Aug 17, 2023

Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second...

Company

Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts

Fineline Cube Aug 17, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...

Company Drug

CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia

Fineline Cube Aug 17, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...

Company Drug

Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment

Fineline Cube Aug 17, 2023

China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...

Company Drug

European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults

Fineline Cube Aug 17, 2023

The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...

Company Drug

BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC

Fineline Cube Aug 17, 2023

Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...

Company Drug

Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Aug 17, 2023

Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...

Company Drug

Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer

Fineline Cube Aug 17, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Company Drug

Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis

Fineline Cube Aug 16, 2023

China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...

Posts pagination

1 … 434 435 436 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.